Clinical Trial Update: Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases [Phase 2]

View source ↗

Summary

Phase II trial evaluating nivolumab in combination with relatlimab for active melanoma brain metastases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma (Skin) | Phase 2 | Status: RECRUITING